Quotient Investors’s Myriad Genetics MYGN Stock Holding History

Quotient Investors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-5,600	Closed	-$210K	–	232
2016 Q1	$210K	Hold	5,600	–	–	0.08%	199
2015 Q4	$242K	Sell	5,600 -900	-14%	-$38K	0.09%	196
2015 Q3	$244K	Sell	6,500 -23,100	-78%	-$820K	0.05%	175
2015 Q2	$1.01M	Sell	29,600 -1,800	-6%	-$61.2K	0.14%	125
2015 Q1	$1.11M	Buy	+31,400	New	+$1.12M	0.15%	115
2014 Q3	–	Sell	-56,100	Closed	-$2.18M	–	275
2014 Q2	$2.18M	Sell	56,100 -75,991	-58%	-$2.83M	0.47%	68
2014 Q1	$4.52M	Sell	132,091 -30,696	-19%	-$951K	1.03%	26
2013 Q4	$3.42M	Buy	162,787 +148,687	+1,055%	+$3.76M	0.8%	39
2013 Q3	$331K	Buy	+14,100	New	+$401K	0.09%	212

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Quotient Investors's MYGN Position: Q2 2016 in Review

Quotient Investors sold out of Myriad Genetics (MYGN) in Q2 2016, closing a stake of 5,600 shares — an estimated $210K sold.

Quotient Investors first reported a position in MYGN in Q3 2013 and held it in 9 quarters. The position peaked at $4.52M in Q1 2014. 252 funds tracked by Wall St. Rank hold MYGN as of Q2 2016.

Quotient Investors reported no remaining Myriad Genetics position as of Q2 2016 after selling out during the quarter.
Quotient Investors sold 5,600 Myriad Genetics shares in Q2 2016, an estimated $210K.
Quotient Investors first reported a position in Myriad Genetics in Q3 2013 and held it in 9 quarters.
Quotient Investors's Myriad Genetics position peaked at $4.52M in Q1 2014.
252 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2016.

Based on Quotient Investors's 13F filing for Q2 2016, filed 11 Jul 2016.